文献速递糖尿病肥胖与代谢综合征

基于肠促胰素的治疗在社会经济方面的问题

Socioeconomic aspects of incretin-based therapy.
PubMed 文献 · Diabetologia · 2023-07-12

本综述基于真实世界证据,探讨基于肠促胰素的治疗(尤其是GLP-1受体激动剂)在不同社会经济群体中应用差异,发现社会经济弱势地区、低收入低教育水平及少数族裔人群使用率更低,而2型糖尿病和心血管疾病负担更重,并讨论减少不平等的策略。

要点

  • 社会经济弱势地区、低收入低教育水平及少数族裔人群GLP-1受体激动剂使用率更低。
  • 这些人群的2型糖尿病和心血管疾病负担更重。
  • 倡导降低GLP-1受体激动剂价格是提高可负担性的关键初始步骤。

核心结论

  • 基于肠促胰素的治疗存在社会经济差异,需通过多方协作策略提高其社会效益。

研究设计与样本

  • 本综述基于真实世界证据,审视基于肠促胰素的治疗利用中的社会经济差异并讨论应对策略。

主要发现

  • 基于真实世界证据,居住在社会经济弱势地区、低收入和低教育水平或属于种族/族裔少数的人群中GLP-1受体激动剂使用率降低,尽管这些个体2型糖尿病和心血管疾病负担更重。
  • contributing因素包括不理想的医疗保险覆盖、基于肠促胰素的治疗可及性有限、经济限制、健康素养低以及医患障碍如提供者偏见。

关键数值与推荐

  • 倡导降低GLP-1受体激动剂价格是提高较低社会经济群体可负担性并从社会角度改善性价比的关键初始步骤。

临床怎么用

  • 通过实施成本效益策略,医疗系统可以放大基于肠促胰素的治疗的社会效益,同时采取措施包括在特定亚群中最大化治疗获益并最小化弱势个体的伤害、增加可及性、提高健康素养和克服医患障碍。
  • 政府、制药公司、医疗保健提供者和糖尿病患者之间的协作方法对于有效实施这些策略以增强基于肠促胰素的治疗的整体社会效益是必要的。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However, socioeconomic disparities in their uptake may constrain the collective advantages offered by these medications to the broader population. In this review we examine the socioeconomic disparities in the utilisation of incretin-based therapies and discuss strategies to address these inequalities. Based on real-world evidence, the uptake of GLP-1 RAs is reduced in people who live in socioeconomically disadvantaged areas, have low income and education level, or belong to racial/ethnic minorities, even though these individuals have a greater burden of type 2 diabetes and cardiovascular disease. Contributing factors include suboptimal health insurance coverage, limited accessibility to incretin-based therapies, financial constraints, low health literacy and physician-patient barriers such as provider bias. Advocating for a reduction in the price of GLP-1 RAs is a pivotal initial step to enhance their affordability among lower socioeconomic groups and improve their value-for-money from a societal perspective. By implementing cost-effective strategies, healthcare systems can amplify the societal benefits of incretin-based therapies, alongside measures that include maximising treatment benefits in specific subpopulations while minimising harms in vulnerable individuals, increasing accessibility, enhancing health literacy and overcoming physician-patient barriers. A collaborative approach between governments, pharmaceutical companies, healthcare providers and people with diabetes is necessary for the effective implementation of these strategies to enhance the overall societal benefits of incretin-based therapies.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Karagiannis T, Bekiari E, Tsapas A, et al. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023. PMID: 37433896. doi:10.1007/s00125-023-05962-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。